Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
Open accessAbstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explore the efficacy and adverse effects (AEs) of tralokinumab for the treatment of patients with moderate to severe AD. A PubMed search for key articles on the emerging clinical data of tralokinumab was performed. Six randomized controlled trials of tralokinumab identified improvements in disease severity measures, including Investigator's Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. Four of these studies demonstrated improvements in quality of life measures with tralokinumab, including pruritus scores, sleep interference scores, Dermatology Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study identified a similar immune response in patients taking tralokinumab to those taking the Tdap and meningococcal vaccines. Upper respiratory infection, conjunctivitis, and headaches were the most common adverse events. The varying criteria to assess changes in AD disease severity across different studies is a limitation of this review. Tralokinumab is another promising biologic option for the treatment of moderate to severe AD, which may reduce disease burden and improve patient quality of life.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Emerging strategies for atopic dermatitis include microbiome modulation, neuroimmune pathway targeting, and biomarker-guided treatment selection.
“Emerging strategies include microbiome modulation, neuroimmune pathway targeting, and biomarker-guided treatment selection, reflecting an evolving precision medicine approach in atopic dermatitis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [16]
The Introduction (page unavailable) links IL-13 to itch signaling, and the Discussion (page unavailable) describes tralokinumab as targeting the IL-13 inflammatory pathway; these passages support a narrower point about targeted treatment in atopic dermatitis. The Discussion also reports reduced S. aureus colonization, but does not present microbiome modulation as a treatment strategy. Neither section describes biomarker-guided treatment selection. (LLM, conf=0.78)
Experimental — accuracy not yet measuredRecent real-world evidence supports the effectiveness of JAK inhibitors in moderate-to-severe atopic dermatitis, particularly in patients with inadequate response to biologic therapies.
“Recent real-world evidence further supports the effectiveness of JAK inhibitors in moderate-to-severe atopic dermatitis, particularly in patients with inadequate response to biologic therapies [11,16,17,18,19].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [16]
Table 2 in the Discussion reports efficacy outcomes for the JAK inhibitors abrocitinib and baricitinib in atopic dermatitis. It does not present real-world evidence or outcomes specifically for patients with inadequate response to biologic therapies; the cited evidence is from randomized trials and reviews of trials. No page number is available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638 · see citing works
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G. L., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C. I., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1406 · Cited by 413 · see citing works
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman‐Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 408 · see citing works
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341 · see citing works
Silverberg, J. I., Toth, D., Bieber, T. R. M., Alexis, A. F., Elewski, B. E., Pink, A., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19573 · Cited by 330 · see citing works
Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.059 · Cited by 328 · see citing works
Silverberg, J. I., Pinter, A., Pulka, G., Poulin, Y., Bouaziz, J.-D., Wollenberg, A., Murrell, D. F., Alexis, A., Lindsey, L., Ahmad, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.013 · Cited by 271 · see citing works
Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis
Drucker, A. M., Ellis, A. G., Bohdanowicz, M., Mashayekhi, S., Yiu, Z. Z. N., Rochwerg, B. N., Giorgio, S. D., Arents, B. W. M., Burton, T., Spuls, P. I., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0796 · Cited by 161 · see citing works
Saeki, H., Kabashima, K., TOKURA, Y., Murata, Y., Shiraishi, A., Tamamura, R., Randazzo, B. P., & Imanaka, K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15493 · Cited by 116 · see citing works
Gutermuth, J., Pink, A., Worm, M., Soldbro, L., Øland, C. B., & Weidinger, S. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20832 · Cited by 92 · see citing works
Wollenberg, A., Beck, L. A., de Bruin-Weller, M. S., Simpson, E. L., Imafuku, S., Boguniewicz, M., Zachariae, R., Olsen, C. K., & Thyssen, J. P. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20810 · Cited by 87 · see citing works
Merola, J. F., Bagel, J., Almgren, P., Røpke, M. A., Lophaven, K. W., Vest, N. S., & Grewal, P. S. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.032 · Cited by 45 · see citing works
Reich, K., DeLozier, A. M., Nunes, F. P., et al. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1839008 · Cited by 42 · see citing works
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis
Silverberg, J. I., Guttman‐Yassky, E., Gooderham, M., Worm, M., Rippon, S., O’Quinn, S., van der Merwe, R., Kragh, N., Kurbasic, A., & Wollenberg, A. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.12.004 · Cited by 21 · see citing works
Fadlalmola, H. A., Albadrani, M. S., Elhusein, A. M., Mohamedsalih, W. E., Swamy, D. S. V., & Mamanao, D. M. (2021) · Dermatology Research and Practice · doi:10.1155/2021/8382761 · Cited by 9 · see citing works
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis With Pruritus
Knox, S. M., & Mahr, T. A. (2021) · PEDIATRICS · doi:10.1542/peds.2021-053843z · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ewulu, A. R., Prajapati, S., & Feldman, S. R. (2023) · Immunotherapy · doi:10.2217/imt-2022-0307 · Cited by 10 · see citing works
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1 · see citing works
“Recent real-world evidence further supports the effectiveness of JAK inhibitors in moderate-to-severe atopic dermatitis, particularly in patients with inadequate response to biologic therapies [11,16–19].”
- Authors
- Kelly, K. A., Perche, P. O., & Feldman, S. R.
- Affiliations
- Wake Forest University Health Sciences (US)
- University of Southern Denmark (DK)
- Corresponding author
- Feldman, Steven R
- Venue
- Clinical Cosmetic and Investigational Dermatology
- Publisher
- Informa UK Limited
- Published
- 2022-06
- Volume
- Volume 15
- Pages
- 1037-1043
- ISSN
- 1178-7015 (ISSN-L)
- PMC
- PMC9172803
- OpenAlex
- W4281666378
- Cited by
- 16
- References
- 16
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Cosmetic and Investigational Dermatology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- tralokinumab, atopic dermatitis, IL-13, type 2 cytokines, monoclonal antibody therapy, biologic therapy, disease severity, quality of life, pruritus, adverse events, vaccine response, Eczema Area and Severity Index, SCORAD
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
